Nevertheless, the characterization of the inducers' mechanisms of action has validated the Bcl-2 family members and the Mcl-1/Noxa axis in particular as potential therapeutic targets in CLL. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.